Business Context and Reporting Period
Company: ICU Medical, Inc.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2004
Business Overview: ICU Medical is a leader in developing and manufacturing proprietary, disposable medical connection systems for intravenous (I.V.) therapy, designed to prevent needlestick injuries and exposure to infectious diseases. The company's primary product is the CLAVE needleless connector. The company is transitioning from a component manufacturer to a producer of complete custom and generic I.V. systems.
Key Financial Metrics
| Metric | 2004 | 2003 | Change |
|---|---|---|---|
| Total Revenue | $75.6 million | $107.4 million | (30%) |
| Net Sales | $72.7 million | $102.7 million | (29%) |
| Gross Profit | $35.7 million | $58.9 million | (39%) |
| Gross Margin (on Net Sales) | 45% | 53% | -8 pts |
| Operating Income | $5.9 million | $34.1 million | (83%) |
| Net Income | $5.0 million | $22.3 million | (78%) |
| Diluted EPS | $0.33 | $1.48 | (78%) |
| Cash from Operations | $25.3 million | $22.8 million | +11% |
| Cash & Liquid Investments | $87.3 million | $73.1 million | +19% |
| Working Capital | $109.6 million | $102.9 million | +7% |
Debt & Liquidity: The company reported no long-term debt. It maintains a strong liquidity position with $87.3 million in cash and liquid investments. The company holds $6.2 million in finance loans receivable (fully secured) but discontinued new lending activities in October 2003.
Material Changes vs. Prior Period
- Revenue Decline: Total revenue dropped 30% primarily due to a $31.5 million decrease in sales to the company's largest customer, Hospira, Inc. (formerly Abbott Laboratories). Hospira reduced purchases to lower its inventory levels of CLAVE products.
- Margin Compression: Gross margin fell from 53% to 45%. This was driven by approximately $5.2 million in unabsorbed overhead due to curtailed production of CLAVE products, lower margins on Punctur-Guard products, and underutilization of the new Italy facility.
- Product Mix Shift: While CLAVE sales (excluding custom systems) dropped 44%, sales of custom I.V. systems increased 15% to $26.2 million. Punctur-Guard sales declined 47% due to lower unit volumes and pricing concessions.
- Expense Increases: Operating expenses rose $5.0 million, largely due to a $1.2 million non-recurring charge for in-process research and development (investment in a heart disease screening device), Sarbanes-Oxley compliance costs, and patent amortization.
Guidance, Outlook, and Risks
Management Commentary & Outlook
- Hospira Relationship: Management expects sales to Hospira to rebound in 2005 as Hospira's inventory levels normalize. Hospira unit sales to end-customers continued to increase throughout 2004 despite reduced purchases from ICU Medical.
- New Agreement (MCDA): On February 25, 2005, the company entered a 20-year Manufacturing, Commercialization, and Development Agreement with Hospira. ICU Medical will acquire Hospira's Salt Lake City facility for ~$35 million and manufacture critical care products exclusively for Hospira. Sales under this agreement are estimated to exceed $50 million in 2005, though initial profits are expected to be small.
- Product Pipeline: New products expected in 2005 include the TEGO Connector (hemodialysis), a new CLAVE Y Site connector, and the Orbit 90 diabetes infusion set.
- Cost Pressures: The company anticipates continued pressure from rising oil-based raw material costs and electricity rates, which may impact profitability if not offset by volume or efficiency gains.
Risks and Contingencies
- Customer Concentration: Hospira accounted for 53% of 2004 revenue. The loss of this customer or further inventory reductions would materially harm the business.
- Competition: The market is intensely competitive. Cardinal Health's acquisition of Alaris (a CLAVE competitor) poses a threat to market share and pricing power.
- Patent Litigation: The company is actively litigating patent infringement claims against B. Braun Medical and Alaris Medical Systems. Outcomes are uncertain and could impact future sales.
- Regulatory: Products are subject to FDA and international regulatory approvals. Delays or failures in clearance could hinder new product introductions.
Investor Verification Checklist
- Hospira Inventory Status: Verify if Hospira has completed its inventory reduction and if purchase orders for 2005 have normalized as management expects.
- MCDA Execution: Confirm the closing of the $35 million acquisition of Hospira's Salt Lake City facility and the timeline for production ramp-up.
- Margin Recovery: Monitor Q1 and Q2 2005 gross margins to see if unabsorbed overhead decreases as production volumes increase.
- Patent Litigation Progress: Review updates on the lawsuits against B. Braun and Alaris, as these are critical to protecting the CLAVE market share.
- Custom I.V. Growth: Assess whether the growth rate of custom I.V. systems can accelerate beyond the 15% growth seen in 2004 to offset potential volatility in CLAVE component sales.